1 Min Read
Sept 25 (Reuters) - Argenx NV
* Argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.